Login to Your Account

Clinical Data to Earn up to $252M

CombinatoRx Gains Adenosine Agonist Rights in Surprise Deal

By Catherine Hollingsworth

Friday, August 14, 2009
Clinical Data Inc. entered a collaboration and licensing agreement with CombinatoRx Inc. to develop an adenosine A2A agonist compound in a combination therapy for multiple myeloma and other B-cell cancers, but the deal might be more strategic than lucrative. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription